Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Bought by Millennium Management LLC

Millennium Management LLC grew its position in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 256.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,329 shares of the company's stock after acquiring an additional 61,403 shares during the quarter. Millennium Management LLC owned approximately 0.52% of Sensus Healthcare worth $590,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at approximately $47,000. Jane Street Group LLC increased its holdings in shares of Sensus Healthcare by 233.7% in the 4th quarter. Jane Street Group LLC now owns 47,623 shares of the company's stock valued at $330,000 after acquiring an additional 33,353 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at approximately $118,000. Northern Trust Corp increased its holdings in shares of Sensus Healthcare by 67.3% in the 4th quarter. Northern Trust Corp now owns 88,720 shares of the company's stock valued at $614,000 after acquiring an additional 35,676 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Sensus Healthcare by 30.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company's stock valued at $2,620,000 after acquiring an additional 88,953 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Trading Down 0.6%

SRTS traded down $0.03 during trading on Wednesday, reaching $5.10. 82,437 shares of the company were exchanged, compared to its average volume of 198,011. The stock has a market cap of $83.87 million, a P/E ratio of 12.75 and a beta of 1.32. The firm has a 50 day moving average of $4.65 and a 200 day moving average of $5.81. Sensus Healthcare, Inc. has a 52 week low of $4.01 and a 52 week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The business had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. As a group, analysts forecast that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SRTS shares. Maxim Group lowered their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Sensus Healthcare in a research note on Friday, April 4th. Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Lake Street Capital lowered their price objective on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.67.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.